CorrespondenceImmunoglobulin replacement therapy: Is there a role for IgA and IgM?
References (7)
- et al.
The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: a comprehensive review of the literature
J Allergy Clin Immunol
(2012) - et al.
Memory B cells in common variable immunodeficiency: clinical associations and sex differences
Clin Immunol
(2008) - et al.
Common variable immunodeficiency disorders: division into distinct clinical phenotypes
Blood
(2008)
Cited by (7)
X-Linked Agammaglobulinaemia: Outcomes in the modern era
2017, Clinical ImmunologyCitation Excerpt :Commercial products contain virtually no IgA or IgM. There are some very limited data suggesting benefit using IgM and IgA rich immunoglobulin products for a carefully selected subset of patients [56,57]. However, most immunoglobulin products continue to be IgA and IgM deplete due to concerns regarding safety and efficacy.
Should therapeutic immunoglobulin be considered a generic product? An evidence-based approach
2013, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Evidence that a particular preparation produces superior clinical outcomes in KD is inconclusive. For individual patients with antibody deficiency evidence of superior outcomes with a particular IVIG product is anecdotal45 and requires carefully designed longitudinal studies for validation. The lack of significant differences in clinical efficacy among different IVIG products, however, does not mean that patients well established on a particular product should be subject to frequent product changes for nonclinical reasons.
Reply
2012, Journal of Allergy and Clinical ImmunologyA new hope? Possibilities of therapeutic IgA antibodies in the treatment of inflammatory lung diseases
2023, Frontiers in ImmunologyLow IgA and IgM Is Associated with a Higher Prevalence of Bronchiectasis in Primary Antibody Deficiency
2017, Journal of Clinical Immunology
Disclosure of potential conflict of interest: S. Kiani-Alikhan has received assistance for travel expenses from Biotest UK. C. Elston has consultant arrangements with Gilead and Pharmaxis and has received lecture fees from Royal Bromptom Cystic Fibrosis. M. A. A. Ibrahim has received consulting fees or honorarium and assistance with travel expenses from Biotest UK. The rest of the authors declare that they have no relevant conflicts of interest.